Geng et al. [43] also demonstrated that in patients with advanced NSCLC, stereotactic-body RT (SBRT) combined with PD-1/PD-L1 inhibitors demonstrated superior outcomes to those of conventional RT combined with PD-1/PD-L1. This evidence concerns the gene CD274 and non-small cell lung carcinoma.